{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:27:52Z","timestamp":1791318472263,"version":"4.3.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ijrobp.2014.12.050","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T04:12:18Z","timestamp":1426824738000},"page":"961-967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Phase 1\/2 Trials of Temozolomide, Motexafin Gadolinium, and 60-Gy Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme: Final Results of RTOG 0513"],"prefix":"10.1016","volume":"91","author":[{"given":"David G.","family":"Brachman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn S.","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Ian","family":"Robins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Bovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Rockhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhee","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter P.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2014.12.050_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"32","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib3","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1200\/JCO.2005.04.6979","volume":"24","author":"Buckner","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib4","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1215\/15228517-2008-052","article-title":"Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients","volume":"10","author":"Pichlmeier","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib6","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa065901","article-title":"Radiotherapy for glioblastoma in the elderly","volume":"356","author":"Keime-Guibert","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11060-012-0832-5","article-title":"Dose dense 1 week on\/1 week off temozolomide in recurrent glioma: A retrospective study","volume":"108","author":"Taal","year":"2012","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1586\/era.11.151","article-title":"American Society of Clinical Oncology 2011 CNS tumor update","volume":"11","author":"Ahluwalia","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib9","first-page":"894","article-title":"Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme","volume":"5","author":"Chang","year":"2007","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ijrobp.2007.04.017","article-title":"Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme","volume":"69","author":"Ford","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib11","doi-asserted-by":"crossref","first-page":"10691","DOI":"10.1074\/jbc.M511373200","article-title":"Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase","volume":"281","author":"Hashemy","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib12","doi-asserted-by":"crossref","first-page":"11676","DOI":"10.1158\/0008-5472.CAN-05-2754","article-title":"Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines","volume":"65","author":"Lecane","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib13","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1158\/0008-5472.CAN-04-4099","article-title":"Motexafin gadolinium disrupts zinc metabolism in human cancer cell lines","volume":"65","author":"Magda","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/1078-0432.CCR-05-0743","article-title":"Motexafin gadolinium taken up\u00a0in-vitro by at least 90% of glioblastoma cell nuclei","volume":"12","author":"De Stasio","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib16","first-page":"889","article-title":"Phase I\/II trial of temozolomide (TMZ), motexafin gadolinium (MGd), and 60 Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme (GBM): Results of RTOG 0513 phase I dose escalation toxicity analysis [abstract]","volume":"10","author":"Brachman","year":"2008","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib17","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2003.12.122","article-title":"Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases","volume":"21","author":"Mehta","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib19","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib20","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2014.12.050_bib21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1227\/NEU.0b013e318223f5a7","article-title":"Application of novel response\/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) working group","volume":"70","author":"Vogelbaum","year":"2012","journal-title":"Neurosurgery"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301614045647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301614045647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T01:11:42Z","timestamp":1566436302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301614045647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0360301614045647"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2014.12.050","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1\/2 Trials of Temozolomide, Motexafin Gadolinium, and 60-Gy Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme: Final Results of RTOG 0513","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2014.12.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}